148 Views

Civitas Therapeutics scores $55 mln Series C

Civitas Therapeutics has closed $55 million in Series C funding. The investors included Adage Capital Management, OrbiMed Advisors, Partner Fund Management, Rock Springs Capital, Sofinnova Ventures, Canaan Partners, RA Capital and Wellington Management Company. Headquartered in Chelsea, Mass., Civitas Therapeutics is a biopharmaceutical company that focuses on developing treatments for Parkinson’s disease.

05132014fundgrowth
136 Views

Bets pay off for venture funds in UC portfolio: VCJ

Last year saw several top performing funds in the University of California’s recent-vintage venture portfolio consolidate performance gains, as others continue to advanced, affiliate magazine Venture Capital Journal reported.

NEA leads Series B round for Loxo Oncology

Loxo Oncology has received $24 million in Series B financing. New Enterprise Associates led the round with participation from previous backers Aisling Capital and OrbiMed Advisors. In addition to the funding, Dr. M. James Barrett, a general partner at NEA, will join Loxo Oncology’s board of directors while Dr. Sara Nayeem, a principal at NEA, will also join the board as an observer. And, the firm has named Dr. Mikel Moyer as chief scientific officer. Loxo Oncology is a a biopharmaceutical company focused on targeted cancer therapies.

Otonomy scores $49 mln Series D funds

Otonomy said Wednesday that it has closed $49 million in Series D funding. The investors included Perceptive Advisors, Federated Kaufmann Funds, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases.

ProNAi Therapeutics raises Series D

ProNAi Therapeutics, a developer of novel nucleic acid therapeutics has closed an oversubscribed $59.5 million Series D financing. The round was led by Vivo Capital and included other new investors Frazier Healthcare Ventures, OrbiMed Advisors, Adams Street Partners, RA Capital Management, Caxton Alternative Management, Hopen Life Science Ventures, Sectoral Asset Management and Janus Capital Management.

SAGE Therapeutics nabs $38 mln Series C funds

SAGE Therapeutics has closed $38 million in Series C financing. Investors included OrbiMed Advisors, EcoR1 Capital Management, Foresite Capital Management, Third Rock Ventures and ARCH Venture Partners. Based in Cambridge, Mass., SAGE Therapeutics is a biopharmaceutical company focused on treating orphan central nervous system disorders.

Clementia Pharmaceuticals appoints

Clementia Pharmaceuticals, a privately held clinical stage biotechnology company has appointed three key executives with rare disease and orphan drug expertise: Donna Grogan, M.D., as chief medical officer, Jeff Packman as chief development officer and Eric Grinstead as chief commercial officer. The company is backed by OrbiMed Advisors and BDC Venture Capital.

Practice Fusion raises $70 mln from Kleiner Perkins, OrbiMed, Deerfield

Healthcare records management company Practice Fusion, which is aiming to grow its healthcare platform, has raised a $70 million Series D round of funding led by Kleiner Perkins Caufield & Byers and institutional investors OrbiMed Advisors and Deerfield Management Co. Existing investors, including Artis Ventures, also participated in the round, which brings the total amount raised by the San Francisco-based company to $134 million. As part of the funding, Beth Seidenberg, general partner at Kleiner Perkins, has joined the company board.

ViewRay Raises Fresh $15M for Its Medical Imaging Technology

ViewRay Inc., a Cleveland-based medical device company, has raised $15 million in fresh funding, raising the total amount raised by the company to nearly $100 million. The company’s machinery, which can produce real-time images of cancerous tumors while the tumors are being treated radiation, raised what has been in its biggest round, a $45 million Series C, last year. ViewRay’s investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital.

Cardioxyl Raises Series B Led By OrbiMed

Cardioxyl Pharmaceuticals has secured $28 million in a Series B financing led by OrbiMed Advisors. New investor Osage University Partners joined OrbiMed and returning investors New Enterprise Associates and The Aurora Funds in the financing.

Principia Biopharma Inks $12.5M

Principia Biopharma Inc., a biopharmaceutical company focused on immunology, autoimmune diseases, and oncology, has raised $12.5 million. Investors include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.

RuiYi and arGEN-X Announce License Agreement

arGEN-X BV has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. arGEN-X is backed by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.

PEHUB Community

Join the 12502 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Create your free online surveys with SurveyMonkey , the world's leading questionnaire tool.

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget